PURPOSE: Dutch guidelines recommend bevacizumab as first-line treatment for neovascular age-related macular degeneration (nAMD) due to its lower cost and comparable outcomes to other anti-VEGF agents. This evidence concerns the gene VEGFA and wet macular degeneration.